C1orf88 Inhibitors
C1orf88 inhibitors encompass a variety of chemical compounds that exert their inhibitory effects through different signaling pathways, ultimately leading to the downregulation of C1orf88's functional activity. Rapamycin is a well-known mTOR inhibitor that, by forming a complex with FKBP12, specifically diminishes mTOR activity, a kinase that regulates cellular growth and proliferation, processes in which C1orf88 is directly involved. LY 294002 and Wortmannin, as PI3K inhibitors, and PD 98059 and U0126, as MEK inhibitors, all target the PI3K/Akt and MAPK/ERK pathways, respectively. These pathways are crucial for cell survival and proliferation, and their inhibition leads to adecreased functional activity of C1orf88 due to its reliance on these pathways for mediating related cellular processes. SB 203580's inhibitory action on p38 MAPK and SP600125's blockade of JNK signaling further contribute to the diminished activity of C1orf88 by interfering with stress response pathways and apoptosis, both of which are believed to involve C1orf88.
Further refining the spectrum of C1orf88 inhibitors are compounds like Y-27632, Sunitinib, Dasatinib, ZM-447439, and PD 0332991. Y-27632, by inhibiting the Rho/ROCK pathway, affects cell shape and motility, indirectly reducing C1orf88's role in these cellular processes. Sunitinib and Dasatinib, through their inhibition of receptor tyrosine kinases and Src family kinases, respectively, stifle the signaling pathways that contribute to cell proliferation and survival where C1orf88's activity is crucial. ZM-447439 targets Aurora kinases, which are essential for mitotic progression, and PD 0332991, a CDK4/6 inhibitor, arrests the cell cycle, both leading to a substantial reduction in C1orf88's associated functional activities. Collectively, these inhibitors orchestrate a concerted downregulation of C1orf88 by targeting specific kinases and signaling cascades that are fundamentally linked to the protein's functional role in the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
By binding to FKBP12 and forming a complex, Rapamycin inhibits mTOR activity. mTOR is a key kinase regulating cell growth, proliferation, and survival. Inhibition of mTOR signaling diminishes C1orf88 activity due to C1orf88's role in these cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3K, LY 294002 blocks the PI3K/Akt pathway. Since C1orf88 is implicated in cell survival regulated by this pathway, its inhibition leads to reduced C1orf88-mediated survival signals. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
As an inhibitor of MEK, PD 98059 interferes with the MAPK/ERK pathway. This inhibition results in decreased phosphorylation and activation of downstream targets, including proteins like C1orf88 that are associated with cell proliferation and differentiation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor that prevents the kinase activity of p38 MAPK. Given that C1orf88 is involved in stress response pathways, blocking p38 MAPK activity can diminish C1orf88's involvement in these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 selectively inhibits MEK1/2, which disrupts the MAPK/ERK pathway. Inhibition of this pathway can lead to reduced activity of proteins like C1orf88 that are involved in cell proliferation and survival. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. Inhibiting PI3K diminishes Akt signaling, leading to decreased activity of downstream proteins such as C1orf88, which is implicated in cell survival and growth pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 blocks JNK signaling, which is involved in stress responses and apoptosis. C1orf88, through its role in these processes, will have diminished activity due to the suppression of JNK activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
As a ROCK inhibitor, Y-27632 inhibits the Rho-associated, coiled-coil containing protein kinase. Rho/ROCK pathway influences cell shape, motility, and adhesion; thus, inhibition of this pathway can diminish C1orf88's role in related cellular processes. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that blocks signaling pathways involved in cell proliferation and survival. By inhibiting these pathways, Sunitinib can reduce the activity of C1orf88 if it is associated with these receptor-mediated processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
As a Src family kinase inhibitor, Dasatinib disrupts multiple signaling pathways involved in cell growth and division. If C1orf88 is involved in these pathways, its activity would be diminished through the inhibition of Src family kinases. | ||||||